Sildenafil is a candidate drug for Alzheimer’s disease: Mechanism‐of‐action observation in patient iPSC‐derived brain organoids and a 5xFAD mouse model

Abstract

Background: We previously identified Sildenafil (a phosphodiesterase type 5 (PDE5) inhibitor) as a candidate drug in Alzheimer’s Disease (AD) using an in silico network medicine approach. However, the clinically meaningful effect size and mechanism‐of‐action of sildenafil in AD treatment is still unclear.